secwatch.observer — SEC 8-K summary
======================================

Issuer:     Y-mAbs Therapeutics, Inc. (—)
CIK:        0001722964
Form:       8-K
Filed at:   2024-07-01T23:59:59+00:00
Accession:  0001558370-24-009643
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Y-mAbs names Peter Pfreundschuh CFO; outgoing CFO Bo Kruse to assist transition to July 31
--------------------------------------------------------------------------------

- Peter Pfreundschuh appointed CFO and Treasurer effective June 28, 2024; succeeds Bo Kruse who will assist transition through July 31, 2024.
- Base salary $500,000; eligible for annual cash bonus up to 45% of base; receives initial option to purchase 170,000 shares and 46,000 RSUs.
- Pfreundschuh previously CFO at Voyager, Frequency, UroGen, Sucampo; earlier roles at J&J, AstraZeneca, Ernst & Young.
- Company highlights commercial traction with DANYELZA and advancement of SADA-PRIT radioimmunotherapy platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1722964/000155837024009643/0001558370-24-009643-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1722964/000155837024009643/ymab-20240627x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-009643

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer